Oncology
For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreFor years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
It took 10 years of treatments for Anisha's IBD to enter remission. But it came back in 2019 — and just as she was about to start treatment, the pandemic hit.
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
Among clinical research’s underrepresented groups: transgender and nonbinary people. One study estimates there are 1.6 million transgender people in the U.S. alone and about one-quarter of those people identify as nonbinary1. In the latest U.K. census, 262,000 respondents identified as transgender, including 30,000 nonbinary respondents2. In clinical trials, these communities have been nearly unaccounted for.
Guided by the dual goals of greater understanding and wider inclusion, Parexel set out to investigate the key barriers to gender diversity in clinical research.
Related Insights
Blog
Generative AI and how we can harness its power in clinical development
Sep 26, 2023
Blog
Clinical pharmacology, modeling and simulation to support FIH study design
Oct 21, 2021
Whitepaper
Case Study Marketing Authorization Transfer
Nov 25, 2021
Whitepaper
Case Study Lifecycle maintenance
Nov 25, 2021
Blog
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 1: Risk-based Quality Management (RBQM) Video Series
Nov 11, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021